Trial Profile

A Randomized, Blinded, Placebo-Controlled Dose-Ranging Phase 1b Study of the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ABI-4334 (Primary)
Indications Hepatitis B
Focus Adverse reactions
Sponsors Assembly Biosciences

Most Recent Events

20 Mar 2025 According to an Assembly Biosciences media release, efficacy, safety and PK data from the remaining 400 mg once-daily oral dosing cohort in a Phase 1b study for ABI-4334 in participants with cHBV infection, anticipated in the first half of 2025,
07 Jan 2025 Planned End Date changed from 22 Apr 2025 to 15 Mar 2025.
07 Jan 2025 Planned primary completion date changed from 19 Dec 2024 to 28 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com